ISPE 2026: A new frontier in case validation for Guillain-Barré syndrome (GBS)

Authors: Joanne Wu ⊕, Pfizer, Inc, New York, NY, Sampada Gandi, MPH ⊕, Pfizer, Inc , New York, NY, Jared Kearn ⊕, Truveta, Inc, Bellevue, WA, Maria Maddalena Lino ⊕, Pfizer, Inc, New York, NY, Joe Engeda ⊕, Truveta, Inc, Bellevue, WA, Michelle R Iannacone ⊕ Pfizer, Inc, New York, NY , Rebecca Naumann ⊕, Truveta, Inc , Bellevue, WA, Younus Muhammad ⊕, Pfizer, Inc, New York, NY, Heather Rubino ⊕, Pfizer, Inc, New York, NY, Priyam Shah ⊕, Truveta, Inc, Bellevue, WA, Sumati Ramsinghani ⊕, Truveta, Inc, Bellevue, WA, Andy Pangilinan ⊕, Truveta, Inc, Bellevue, WA, Puja Rao ⊕, Truveta, Inc, Bellevue,